检索结果-南通市图书馆

New drugs for the treatment of metastatic colorectal cancer

World Journal of Gastrointestinal Oncology 2021年第11期13卷 1551-1560页

作者： sara cherri Michela Libertini Alberto Zaniboni Department of Oncology Fondazione PoliambulanzaBrescia 25124Italy

Colorectal cancer(CRC)represents one of the most frequent malignancies in terms of incidence and mortality,thus representing the third leading cause of cancer death *** the last decade,few drugs have enriched the treatment landscape of metastatic CRC and have significantly affected *** other neoplasms,metastatic CRC patients who have exhausted treatment options often still maintain a good performance *** are many challenges to increasing potential treatment options,notably a better understanding of disease biology and the mechanisms of resistance underlying cancer treatment *** development of new drugs for metastatic CRC certainly represents one of the most important challenges in medical *** article discusses the main limitations in the development of new drugs and potential future *** particular,we addressed three questions:(1)The main limitations of targeted therapy in the treatment of metastatic CRC(mCRC);(2)New target armamentarium that could escape primary and secondary resistance and lead to more personalized mCRC therapy;and(3)Future directions.

关键词： Colon cancer Colon rectal cancer New drugs Drug resistance Metastatic colorectal cancer

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Pancreatic adenocarcinoma:Beyond first line,where are we?

引用

World Journal of Gastroenterology 2021年第17期27卷 1847-1863页

作者： sara cherri Silvia Noventa Alberto Zaniboni Department of Oncology Fondazione PoliambulanzaBrescia 25124Italy

Pancreatic cancer is considered one of the most aggressive cancers,with an increasing incidence in recent *** date,chemotherapy is still the standard of care for advanced metastatic disease,unfortunately providing only a slight advantage in terms of *** molecular and cellular characteristics of pancreatic cancer cells,as well as the cells that characterize the pancreatic tumour microenvironment,are the basis of the mechanisms of resistance to *** progression during first-line treatment,few patients are eligible for secondline treatment due to the loss of performance *** date,a clear survival advantage has not yet been demonstrated for second-line *** medicine could be the key to increasing responses to cancer treatment and finally impacting survival in this difficult-to-treat *** this review,we analyze current recommendations in the second-line setting and potential future prospects.

关键词： Pancreatic adenocarcinoma Second-line Chemotherapy Targeted therapy Immunotherapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Tocilizumab as treatment for COVID-19:A systematic review and meta-analysis

引用

World Journal of Methodology 2021年第3期11卷 95-109页

作者： Fausto Petrelli sara cherri Michele Ghidini Gianluca Perego Antonio Ghidini Alberto Zaniboni Oncology Unit Asst Bergamo OvestMilano 20124Italy Department of Clinical Oncology Fondazione PoliambulanzaBrescia 25124Italy Medical Oncology Unit Fondazione IRCCS Ca'Granda Ospedale Maggiore PoliclinicoMilanItaly Pharmacy Unit San Raffaele HospitalMilano 20100Italy Department of Medicine Casa di Cura IgeaMilano 20100Italy Department of Oncology Fondazione PoliambulanzaBrescia 25124Italy

BACKGROUNDThe majority of patients with coronavirus disease 2019 (COVID-19) have goodprognoses, but some develop a critical illness that can lead to death. Evidenceshows severe acute respiratory syndrome is closely related to the inducedcytokine storm. Interleukin-6 is a key player;its role in systemic inflammation iswell *** evaluate the effect of tocilizumab (TCZ), an interleukin-6 receptor antagonist,on the outcomes for patients with COVID-19 ***, EMBASE, SCOPUS, Web of Science, MedRxiv, Science Direct, and theCochrane Library were searched from inception to 9th June 2020 for observationalor prospective studies reporting results of hospitalized adult patients withCOVID-19 infection treated with TCZ. Effect sizes were reported as odds ratios(ORs) with 95% confidence intervals (CIs), and an OR less than 1 was associatedwith a better outcome in those treated with *** 13476 patients (33 studies;n = 3264 received TCZ) with COVID-19pneumonia and various degree of severity were included. Outcome wasimproved with TCZ. In the primary analysis (n = 19 studies reporting data),mortality was reduced in patients treated with TCZ (OR = 0.64, 95%CI: 0.47-0.87;P < 0.01). In 9 studies where risk of death with TCZ use was controlled for othervariables mortality was reduced by 57% (OR = 0.43, 95%CI: 0.27-0.7;P < 0.01).Intensive care need (mechanical ventilation) was also reduced (OR = 0.36, 95%CI:0.14-0.89;P = 0.02).CONCLUSIONIn COVID-19-infected patients treated with TCZ, outcome may be improvedcompared to those not treated with TCZ.

关键词： Tocilizumab COVID-19 Pandemic Treatment Meta-analysis Review

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：